KOL Perspectives: Fistulising Crohn’s disease
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› The briefing includes analysis of KOL opinion on the following topic areas:
– Current treatment of FCD
– Ustekinumab in FCD
– Novel therapies for treatment of FCD
– FCD clinical trial design
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs)
› In total, we conducted interviews with x KOLs:
– 5 Europe-based & 5 US-based
– Interviews performed during Q3 2017
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
UST anticipated to be used after IFX (which is approved for FCD, and is also available as a biosimilar)
Expected use of Cx601 is primarily in anti-TNF failure patients, but opinions divided on use as either a mono or combination therapy
Ideal endpoint for measuring efficacy in FCD is combined remission (fistula closure + MRI imaging)
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on " Fistulising Crohn's disease "
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Crohn's disease
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Janssen
TiGenix
Gilead
Galapagos
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.